Researchers Find a Blood Test Could Predict Who Benefits from Immunotherapy

Aug 4, 2020

From left to right, Drs. Lillian Siu, Scott Bratman and Trevor PughFrom left to right, Drs. Lillian Siu, Scott Bratman and Trevor Pugh

University of Toronto researchers have found that a test which detects changing levels of tumour fragments in the blood may be an easy, non-invasive and quick way to predict who will benefit from immunotherapy, a treatment option for advanced cancers.

Although immunotherapy has been shown to shrink tumours and prolong survival for patients for whom other treatments have failed, about 20 to 30 per cent of patients benefit from it. Clinicians don’t yet know ahead of time who this subset of patients is. 

Understanding this is crucial, since immunotherapy can have severe side effects in a small percentage of patients and knowing whether to begin or continue would be helpful for patients weighing different treatment options.

A team of scientists and clinicians addressed this question with a novel study evaluating various cancer patients’ response to a specific immunotherapy drug via a customized test based on each patient’s tumour profile. 

They found that individual response to treatment can be predicted within weeks, based on increasing or decreasing levels of DNA fragments which are shed from the tumour into the blood. 

Genomic testing with powerful new technologies can detect the same genetic mutations in the fragments circulating in the blood as in the actual tumour. These fragments are called circulating DNA or ctDNA.

Specifically, the study found that a decrease in these circulating tumour DNA fragments at six – seven weeks after treatment with the immunotherapy drug pembrolizumab was associated with a beneficial response to the drug and longer survival.

The study, “Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab,” was published in Nature Cancer this week.

Dr. Lillian Siu, a professor in the Department of Medicine at the University of Toronto and Senior Scientist and medical oncologist at Princess Margaret Cancer Centre, BMO Chair in Precision Cancer Genomics, noted that the study is one of the first studies across a broad spectrum of tumours to show that measuring levels of ctDNA could be useful as a predictor of who responds well to immunotherapy.

“It’s like a molecular CT scan that gives us a molecular dimension, an added layer of information to know whether a tumour is growing or not,” says Siu, a co-senior author of the paper. “That’s why this is so exciting. It helps to predict early on what may happen over time. Although important, computerized tomography (CT) and other scans alone will not tell us what we need to know quickly or accurately enough.”

Dr. Scott Bratman, who is an associate professor of radiation oncology and medical biophysics and first author on the paper, points out that it may take many months to detect whether a tumour is shrinking with various imaging scans.

“New next-generation sequencing technologies can detect and measure these tiny bits of cellular debris floating in the blood stream accurately and sensitively, allowing us to pinpoint quite quickly whether the cancer is active,” says Bratman, a radiation oncologist and Senior Scientist at Princess Margaret. 

The prospective study analyzed the change in ctDNA from 74 patients, with different types of advanced cancers, being treated with pembrolizumab.  
In order to customize or personalize the test, all the genes from the tumour biopsy tissue of each patient were sequenced or decoded, with specific attention to the mutations that occur in cancer. 

These cancer mutations ranged from dozens to tens of thousands of mutations per tissue sample, differing according to cancer type.

Sixteen genetic mutations for each patient were then selected for a specific test to be developed and customized to detect personalized ctDNA of each patient via a simple blood sample.

“When we looked at all 20,000 genes in each cancer, the range of mutations in different individuals was huge due to the many different cancer types in the study,” says Dr. Trevor Pugh, a co-senior author on the paper and an associate professor in the Department of Medical Biophysics. 

“The novelty is that, rather than taking a one-size-fits-all approach, we designed a personalized blood test for each person based on their own cancer’s mutation list,” says Pugh, a Senior Scientist at Princess Margaret and Director of Genomics at the Ontario Institute for Cancer Research.      
Of the 74 patients, 33 had a decrease in ctDNA levels from their original baseline levels to week six to seven after treatment with the drug. These patients had better treatment responses and longer survival. Even more striking was that all 12 patients who had clearance of the ctDNA to undetectable levels during treatment were still alive at a median follow-up of 25 months. 

Conversely, a rise in ctDNA levels was linked to a rapid disease progression in most patients, and poor survival.  

“Few studies have used a clinical biomarker across different types of cancers,” says Siu, who is also the Clinical Lead for the Tumor Immunotherapy Program at the Princess Margaret, adding that “the observation that ctDNA clearance during treatment and its link to long-term survival is novel and provocative, suggesting that this biological marker can have broad clinical impact.”

This research was funded by the Princess Margaret Cancer Foundation, Ontario Institute for Cancer Research, Terry Fox Research Institute, Gattuso-Slaight Personalized Cancer Fund, BMO Chair in Precision Cancer Genomics, Canada Research Chair in Translational Genomics, Canada Foundation for Innovation, Ontario Ministry of Research and Innovation, and Merck for the study drug. 


Temerty Medicine
RT : 1/4 key concerns in 🇨🇦: the continuing increase in daily case counts nationally together with increased ho…
Temerty Medicine
Some concerns are being raised about privately-offered paid COVID-19 tests that can be taken at home. Is this makin…

Researchers are mobilizing against the novel SARS-CoV-2 coronavirus and COVID-19.

Make a gift and support their important work.
Sep 23 – Nov 11
Safer Opioid Prescribing
Course | 7:00am–9:00pm
23 – 26
2020 Young Investigator Forum
Symposium | 8:00am–4:00pm
Sep 26 Multidisciplinary Care in IBD (MCIBD) 2020 - Strength Through Shared Knowledge
Conference | 9:00am–1:30pm
2 – 3
Demystifying Neurology for the Non-Neurologist
Conference | 7:30am–3:15pm
Oct 5 – May 6
Academic Health Leadership Training – Now Accepting Applications 2020-2021 Cohort
Course | 8:00am–5:00pm
Oct 7 Medical Record-Keeping
| 8:30am–4:30pm
Oct 13 – Jun 8
Certificate Program in CPD Foundations
Course | 12:00pm–1:30pm